Future Perspective on Pharmacogenomics of Severe Hypoglycemia Associated with Sulfonylureas: Reply from the Authors

Ryosuke Satoa Department of Endocrinology & Metabolism, Division of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan and Department of Endocrinology & Metabolism, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.Correspondence[email protected]

Hiroshi Watanabeb Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan

Rieko Genmac Department of Endocrinology & Metabolism, Seirei Hamamatsu General Hospital, Hamamatsu, Japan

Masahiro Takeuchid Reseach Center for Clinical Pharmacology, Kitasato University, Tokyo, Japan

Masato Maekawae Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan

Hirotoshi Nakamuraf Department of Endocrinology & Metabolism, Division of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan

Abstract

A letter in response to: Holstein JD, Kovacs P, Patzer O, Stumvoll M, Holstein A. The Ser1369Ala variant of ABCC8 and the risk for severe sulfonylurea-induced hypoglycemia in German patients with Type 2 diabetes. Pharmacogenomics 13(1), 5–7 (2012).

Disclaimer

This work is the opinion of the authors and does not represent the views of Future Medicine or its employees.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Future Perspective on Pharmacogenomics of Severe Hypoglycemia Associated with Sulfonylureas: Reply from the Authors

Information for

Open access

Opportunities

Help and information

Future Perspective on Pharmacogenomics of Severe Hypoglycemia Associated with Sulfonylureas: Reply from the Authors

Abstract

Disclaimer

Financial & competing interests disclosure

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature